Fig. 3

Male and female GBM astrocytes display sex differences in response to serum deprivation, CDKi treatment and chemotherapy. a Male and female GBM astrocytes were grown in either 10% or 0.1% serum and cell number was measured over the course of 96 h by trypan blue exclusion. The differences in growth rates (n = 3) in 0.1% serum was significant with p < 0.0001 as determined by two-way ANOVA. b Representative dose response curve for palbociclid treatment of male and female GBM astrocytes. Cell viability was measured with CellTiter Glo. IC50 values were calculated using four-parameter non-linear regression analysis in Graphpad Prism. c Male and female GBM astrocytes were treated with etoposide (10 μg/ml) or vehicle for 24 h. At that time, media was changed to 10% FBS supplemented DMEM/F12 and cell number was measured over the course of 4 days by trypan blue exclusion. The differences in growth rates were significant with p = 0.0001 as determined by two-way ANOVA (n = 3)